These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28301705)

  • 41. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
    Finkelstein PE
    AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587
    [No Abstract]   [Full Text] [Related]  

  • 42. A critical tipping point.
    Zuckerman MB
    US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
    [No Abstract]   [Full Text] [Related]  

  • 43. Encouraging research and development of pediatric medical devices through legislative and regulatory action: the Pediatric Medical Device Safety and Improvement Act of 2007 in context.
    Bleicher EW
    Food Drug Law J; 2009; 64(3):531-64. PubMed ID: 19999642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibiotic research and development: business as usual?
    Harbarth S; Theuretzbacher U; Hackett J;
    J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The global challenge of new classes of antibacterial agents: an industry perspective.
    Fernandes P
    Curr Opin Pharmacol; 2015 Oct; 24():7-11. PubMed ID: 26119487
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Uneasy alliance--clinical investigators and the pharmaceutical industry.
    Bodenheimer T
    N Engl J Med; 2000 May; 342(20):1539-44. PubMed ID: 10816196
    [No Abstract]   [Full Text] [Related]  

  • 47. Bring the magic back to the bullets.
    Nat Biotechnol; 2006 Dec; 24(12):1489. PubMed ID: 17160046
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
    Milton MN; Horvath CJ
    Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
    [No Abstract]   [Full Text] [Related]  

  • 49. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments.
    Rex JH; Eisenstein BI; Alder J; Goldberger M; Meyer R; Dane A; Friedland I; Knirsch C; Sanhai WR; Tomayko J; Lancaster C; Jackson J
    Lancet Infect Dis; 2013 Mar; 13(3):269-75. PubMed ID: 23332713
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulatory Considerations for the Approval of Drugs Against Histomoniasis (Blackhead Disease) in Turkeys, Chickens, and Game Birds in the United States.
    Regmi PR; Shaw AL; Hungerford LL; Messenheimer JR; Zhou T; Pillai P; Omer A; Gilbert JM
    Avian Dis; 2016 Dec; 60(4):725-730. PubMed ID: 27902913
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 1992 Le Tourneau Award. Problems with pharmaceutical regulation in the United States. Drug lag and orphan drugs.
    Henry V
    J Leg Med; 1993 Dec; 14(4):617-39. PubMed ID: 8308452
    [No Abstract]   [Full Text] [Related]  

  • 52. Better regulation of industry-sponsored clinical trials is long overdue.
    Wynia M; Boren D
    J Law Med Ethics; 2009; 37(3):410-9, 395. PubMed ID: 19723252
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
    Kesselheim AS; Outterson K
    Health Aff (Millwood); 2010 Sep; 29(9):1689-96. PubMed ID: 20820028
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibiotics: the changing regulatory and pharmaceutical industry paradigm.
    Bax R; Green S
    J Antimicrob Chemother; 2015 May; 70(5):1281-4. PubMed ID: 25634991
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
    Kesselheim AS; Mello MM
    Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibacterial drug discovery in the 21st century.
    Bush K
    Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():10-7. PubMed ID: 15522035
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Walking the drug regulatory tightrope.
    Dove A
    Nat Biotechnol; 2003 May; 21(5):495-8. PubMed ID: 12721571
    [No Abstract]   [Full Text] [Related]  

  • 58. The 21st century cures act: Opportunities and challenges.
    Sarpatwari A; Kesselheim AS
    Clin Pharmacol Ther; 2015 Dec; 98(6):575-7. PubMed ID: 26264909
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Moving goalposts--regulatory oversight of antibacterial drugs.
    Brenner R; Ellis-Grosse EJ; Echols R
    Nat Biotechnol; 2006 Dec; 24(12):1515-20. PubMed ID: 17160053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The future of antibiotics.
    Spellberg B
    Crit Care; 2014 Jun; 18(3):228. PubMed ID: 25043962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.